Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,185,385.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $545.83, for a total value of $5,185,385.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,113,210.79. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Stock Up 0.1%

Shares of UTHR stock opened at $545.96 on Friday. The stock has a market cap of $23.17 billion, a PE ratio of 20.15, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. The business has a 50-day simple moving average of $566.75 and a 200-day simple moving average of $521.34. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the firm earned $6.63 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Geneos Wealth Management Inc. increased its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares in the last quarter. Jump Financial LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at about $277,000. Cerity Partners LLC increased its stake in shares of United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia increased its stake in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.